# Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

Source: https://onco.cc/trials/nct00777153/  
OnCo record `nct00777153` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cediranib in Glioma & glioblastoma, run by AstraZeneca, completed.

## Summary

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma is a phase 3 interventional study registered as NCT00777153 by AstraZeneca, with 423 participants recorded, started 2008-10 and reaching its primary completion in 2010-04. Interventions recorded: Cediranib, Cediranib, Lomustine Chemotherapy, Placebo Cediranib. Conditions recorded: Recurrent Glioblastoma.

Linked to the drug Cediranib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-24
- Also known as: REGAL
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00777153
- Phase: 3
- Setting: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
- Sponsor: AstraZeneca
- Enrolled: 423
- Outcomes: Progression Free Survival (PFS): Cediranib 30mg 92 days vs Cediranib 20mg+ Lomustine 110mg 125 days vs Lomustine 110mg 82 days; Overall Survival (OS): Cediranib 30mg 8 months vs Cediranib 20mg + Lomustine 110mg 9.4 months vs Lomustine 110mg 9.8 months

## Sources

- ClinicalTrials.gov NCT00777153: https://clinicaltrials.gov/study/NCT00777153

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Cediranib](https://onco.cc/drugs/cediranib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct00777153.json